Enbrel market seen rising to $23.64M by 2030 as biosimilars pressure grows

The Business Research Company says the global Enbrel (etanercept) market is set to grow from $17.7 million in 2025 to $23.64 million by 2030, driven by autoimmune disease prevalence and demand for biologics. North America led the market in 2025, while Asia-Pacific is forecast to grow fastest as biosimilars and home treatment reshape the category.

Why it matters: - The Enbrel (etanercept) market is expanding even as biosimilar competition intensifies. - Rising autoimmune disease prevalence is keeping demand for biologic treatments in focus. - The shift toward home-based care and self-administration could change how patients access treatment.

What happened: - The Business Research Company released its Global Market Report 2026 for the Enbrel (etanercept) market. - The report values the market at $17.7 million in 2025 and forecasts $18.8 million in 2026. - The report projects the market will reach $23.64 million by 2030. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America held the largest market share in 2025. - Asia-Pacific is forecast to grow the fastest over the next several years.

The details: - The report puts the 2025-2026 compound annual growth rate at 6.2%. - The report puts the 2026-2030 compound annual growth rate at 5.9%. - Historical growth is tied to higher autoimmune disease prevalence, wider access to biologic therapies, more rheumatology care services, greater acceptance of injectable biologics and higher patient awareness. - Forecast growth is tied to stronger biosimilar competition, demand for lower-cost biologic drugs, home-based treatment, value-based care and drug-delivery innovation. - The report identifies wider use of biosimilar tumor necrosis factor inhibitors as a key trend. - The report also points to advances in self-administration devices, longer-term maintenance therapy, broader autoimmune indications and stronger treatment-adherence efforts. - Enbrel is a biologic medication that targets tumor necrosis factor, a protein involved in inflammation. - Enbrel is administered by subcutaneous injection and can be given by healthcare professionals or self-administered at home. - The therapy is used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis.

Between the lines: - The market’s growth outlook suggests that branded biologics still have room to expand, but pricing and access pressure from biosimilars will likely shape the next phase. - Home treatment and self-administration trends favor products that are easy to use outside clinical settings. - The report’s regional split reinforces a familiar pattern: mature markets lead in value, while faster growth is moving toward regions with rising healthcare investment and diagnosis rates. - Australian Institute of Health and Welfare data cited in the report showed about 514,000 Australians, or 2.0%, were living with rheumatoid arthritis in 2022. - That condition accounted for 2.0% of the overall disease burden and 16% of musculoskeletal disease burden in 2023, and contributed to 1,322 deaths, or 0.7% of all fatalities.

What's next: - The report expects biosimilar TNF inhibitors to gain broader use over the forecast period. - The report expects continued innovation in biologic drug delivery systems. - The report expects stronger demand for affordable biologic medicines and long-term maintenance treatment. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market-hotspot infographics and future-trend analysis. - The full report is available here. - A free sample is available here.